HeartSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HeartSciences Inc. on July 16, 2025. The company, incorporated in Texas, is an emerging growth company reporting on the status of its Regulation A Offering.
Key Financial Metrics and Capital Structure
- Gross Proceeds Raised: $2.8 million as of July 16, 2025.
- Units Issued: 797,452 Units (out of a maximum offering of 4,285,714 Units).
- Offering Price: $3.50 per Unit.
- Maximum Offering Amount: $15,000,000.
- Common Stock Outstanding: 1,797,914 shares as of July 16, 2025.
- Preferred Stock Conversions: 486,815 shares of Series D Convertible Preferred Stock converted to Common Stock.
Note: The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios beyond the proceeds from this specific offering.
Material Changes and Offering Details
The filing details the progress of a Regulation A Offering qualified by the SEC on March 10, 2025. Each Unit consists of one share of Series D Convertible Preferred Stock and one warrant to purchase one share of Common Stock at an exercise price of $5.00. The company has completed several closings, resulting in the issuance of approximately 18.6% of the maximum authorized Units.
Outlook and Management Commentary
Management has not provided forward-looking guidance, risk factors, or commentary on future operations within this specific filing. The report focuses solely on the execution of the capital raise and the resulting equity structure changes.
Investor Verification Checklist
- Verify the remaining capacity of the Regulation A Offering ($12.2 million remaining).
- Confirm the dilution impact of the 486,815 preferred share conversions on existing shareholders.
- Review the terms of the warrants included in the Units, specifically the $5.00 exercise price relative to current market conditions.
- Check subsequent filings for updates on the use of the $2.8 million in gross proceeds.